Lyell Immunopharma, Inc. (LYEL)
NASDAQ · Healthcare
Lyell Immunopharma, Inc. Income Statement 2019–2025
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenue | 36,000 | 61,000 | 130,000 | 84.7M | 10.7M | 7.8M | 657,000 |
| Gross Profit | — | — | — | — | — | — | — |
| Profitability | |||||||
| Operating Income | -269.4M | -358.8M | -247.0M | -187.1M | -214.8M | -211.9M | -102.1M |
| EBITDA | -257.9M | -339.1M | -226.8M | -169.0M | -201.2M | -207.6M | -100.8M |
| Net Income | -274.4M | -343.0M | -234.6M | -183.1M | -250.2M | -204.5M | -129.4M |
| Per Share Data | |||||||
| EPS (diluted) | — | — | — | — | — | — | — |
| Shares Outstanding (dil.) | 17M | 13M | 13M | 247M | 136M | 13M | 0M |
Lyell Immunopharma, Inc. Income Statement — FAQ
Lyell Immunopharma, Inc. (LYEL) income statement over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LYEL's income statement history?
The chart and table above show Lyell Immunopharma, Inc.'s income statement by year and by quarter, including the growth rate.